Dynogen reports positive results in Phase 2 IBS-c study
Dynogen Pharmaceuticals, Inc. today reported positive results of its randomized, double-blind, placebo–controlled, parallel group Phase 2 trial of DDP733 in patients with irritable bowel syndrome with constipation (IBS-c). DDP733 achieved an overall clinical response rate of 54% in patients receiving a dose of 1.4 mg t.i.d. compared to a 15% clinical response rate for patients receiving placebo. This was a statistically significant difference in a clinical endpoint which has been accepted by the FDA as a registration endpoint for this indication. The drug was well tolerated in this study. Detailed results will be submitted for disclosure in a peer-reviewed journal or at a future medical conference.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.